Drug Trial Radar · NCT06996093
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
Last checked: Nov 20, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
2,508
Planned (sponsor's estimate)
Start
Jun 2, 2025
Primary completion
Jun 1, 2030
Study completion Jun 1, 2034
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, randomized, open-label, multicenter phase III study to explore chemotherapy omission in hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer with lymph node negative disease receiving adjuvant endocrine therapy and cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitor.
Conditions
- Breast Cancer
Interventions
4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapyDrug
4 cycles of TC (docetaxel + cyclophosphamide) adjuvant chemotherapy
aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitorDrug
aromatase inhibitor (± ovarian suppression) plus CDK4/6 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- invasive disease free survivalTime frame: 4 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.